A broad portfolio of tools

Throughout the history of medicine, the use of chemical compounds for the production of chemically synthesized drugs has predominated.

With the advancement of scientific technique, the use of biotechnology in health has opened the door to a new generation of medicines, biological ones. Unlike those of chemical origin, these types of drugs are proteins and are based on the study of human biology.

While the first biotechnological drugs, such as insulin, were modified versions of human proteins, complex molecular structures can now be designed by studying the molecular machinery of cells and using sophisticated technologies.

Taking advantage of the full potential offered by protein engineering, at Amgen we investigate human biology to advance the development of increasingly personalized medicine. Currently, we have a solid portfolio of 13 different therapeutic modalities to provide a broader response to many serious diseases or with treatment needs not yet covered.

Of the 13 modalities, 5 are based on immunotherapy and are intended for the treatment of a wide variety of tumors.


Learn more about our pipeline